Valneva and the Serum Institute of India (SII) have ended a license agreement for chikungunya vaccine supply in Asia after ...

In early December, the 2025 updates of China’s NRDL were finalised with a total of 114 drugs, including Western drugs and ...

Outlook Therapeutics has received the US FDA's CRL regarding the BLA resubmission for ONS-5010/LYTENAVA to treat wet AMD.

Maryland’s Prescription Drug Affordability Board (PDAB) serves as a bellwether for how other states may address high drug ...

Data indicating unequal treatment effects in women has prompted calls for more nuance in Alzheimer’s diagnosis and drug ...

Johnson & Johnson (J&J) has completed its acquisition of Halda Therapeutics, a clinical-stage biotechnology company, for ...

Sanofi has agreed to acquire hepatitis B vaccine manufacturer Dynavax for an equity value of around $2.2bn, bolstering the ...

Genmab is discontinuing development of acasunlimab after a pipeline review, pivoting focus to other oncology antibodies.

Emmaus Life Sciences has entered into a licensing and exclusive distribution agreement with NeoImmuneTech (NIT) for Endari, a ...

Innovent Biologics has received China’s NMPA approval for the NDA for Tabosun, a CTLA-4 monoclonal antibody for colon cancer.

With the latest batch’s agreements, only three out of the 17 drugmakers initially targeted by Trump have not signed pricing ...

AstraZeneca's Andexxa will no longer be sold or manufactured in the US following FDA concerns around the drug's association ...